K2 and Spice are common names for a changing group of products containing synthetic cannabinoid receptor agonists. They are often sold as herbal incense or plant material treated with laboratory-made chemicals, but the names do not refer to one fixed substance. Different products, and even different portions of the same packet, can contain different synthetic cannabinoids and concentrations. This variability helps explain their unpredictable effects and the range of severe outcomes documented in clinical reports.
What K2 and Spice actually contain
Early products were typically dried plant material sprayed or soaked with synthetic cannabinoids. The plant matter itself was not the main source of psychoactive activity; it served as a carrier for the active chemicals. Packaging often used labels such as “herbal incense” or “not for human consumption”, while the products were marketed in ways that implied cannabis-like effects.
There is no single chemical formula for K2 or Spice. Products have contained compounds from several structural families, including naphthoylindoles, cyclohexylphenols, indazole- and indole-3-carboxamides, and later generations of highly potent synthetic cannabinoids. Examples identified in seized material and toxicology investigations include JWH-018, JWH-073, AM-2201, CP-47,497, UR-144, XLR-11, AB-FUBINACA and AB-CHMINACA.
As individual compounds become controlled or less available, manufacturers may replace them with different analogues. This has led to successive waves of products with different compositions. A package name or logo is therefore not a reliable indication of its chemical contents (The K2/Spice phenomenon: emergence, identification and metabolic characterisation, 2014).
How synthetic cannabinoids act
Most compounds found in K2 and Spice act on the cannabinoid receptors CB1 and CB2. CB1 receptors are abundant in the central nervous system and are responsible for many of the psychoactive effects associated with cannabinoids. CB2 receptors are expressed prominently in immune and peripheral tissues, although their distribution is not limited to those sites.
THC, the main intoxicating constituent of cannabis, is generally a partial agonist at cannabinoid receptors. Many synthetic cannabinoids found in K2 and Spice act as full agonists or show higher efficacy in laboratory assays. Some also have very high receptor affinity. This difference can produce stronger or less predictable receptor activation than would be expected from cannabis, although the clinical effect of any particular compound also depends on its distribution, metabolism and other pharmacological properties.
These compounds differ in their pharmacology. A product containing one JWH compound may behave differently from a later product containing an indazole carboxamide. Even within a chemical family, small structural changes can alter receptor affinity, efficacy and metabolism.
Why product effects are unpredictable
Several factors contribute to the variable effects of K2 and Spice:
- Changing ingredients: the active chemicals can differ between brands, batches and regions.
- Uneven distribution: sprayed material may contain areas with much higher concentrations than others, sometimes described as “hot spots”.
- Different receptor activity: compounds vary in CB1 potency, efficacy and selectivity.
- Unknown metabolites: some metabolites remain biologically active or complicate toxicological interpretation.
- Co-exposures: products or clinical cases may involve additional drugs that contribute to the presentation.
Laboratory analyses have repeatedly found mixtures of synthetic cannabinoids in products sold under the same general name. This makes it difficult to connect a reported reaction to one specific ingredient unless the product and biological samples have been analysed.
Reported effects
Some users describe cannabis-like effects, including altered perception, relaxation or changes in mood. Clinical presentations, however, can be much more severe than those usually associated with cannabis. Reported symptoms include anxiety, panic, paranoia, agitation, confusion, hallucinations, delirium and psychosis.
Neurological and psychiatric effects
Seizures, severe agitation, reduced consciousness and catatonia have all been described in clinical reports. Persistent psychotic symptoms have also been reported after intoxication. People with a history of psychiatric illness may be particularly vulnerable to destabilisation, although serious reactions have also occurred in people without a known psychiatric history.
Cardiovascular and physical effects
Tachycardia is one of the most frequently reported findings. Other observations include changes in blood pressure, palpitations, chest discomfort, nausea, vomiting, sweating, tremor and impaired coordination. Severe cases may involve respiratory compromise, kidney injury, cardiovascular complications or other organ damage.
Clinical and toxicological evidence
A 2023 systematic review examined 64 articles reporting human effects of synthetic cannabinoids in K2/Spice. The review included ten original research papers and 54 case studies. Fourteen studies reported deaths associated with synthetic cannabinoid use. Tachycardia and seizures were the most frequently described toxic effects, while severe neuropsychiatric presentations were prominent in reports involving later-generation compounds (Campello de Oliveira and colleagues, 2023).
Interpreting the review’s findings requires care: many reports involved several substances, and the specific synthetic cannabinoid was not always identified. A death reported in association with a product does not necessarily mean that one named ingredient was the sole cause. Nevertheless, the number and severity of documented cases establish that these products can cause life-threatening intoxication.
Dependence and withdrawal
Repeated use of synthetic cannabinoids has been associated with tolerance, craving and withdrawal symptoms. Reported withdrawal features include anxiety, irritability, insomnia, sweating, nausea, tremor and, in severe cases, marked agitation or seizures. The risk is difficult to quantify because K2/Spice products vary substantially in composition and potency.
Clinical reviews describe dependence as a concern, particularly among people who use synthetic cannabinoids frequently or who have limited access to reliable information about the products they are consuming. The evidence does not establish the same dependence profile for every synthetic cannabinoid.
Detection and forensic analysis
Routine drug screens designed for cannabis do not reliably detect most synthetic cannabinoid receptor agonists. Testing generally requires targeted analytical methods such as liquid chromatography coupled with tandem mass spectrometry. Because the parent compound may be rapidly metabolised, laboratories often look for specific metabolites in urine or blood.
The rapid emergence of new analogues creates an ongoing challenge for forensic laboratories. A test panel may detect compounds that were common when it was developed but miss newer substances or metabolites. Reference standards and analytical libraries therefore need regular updating.
Research limitations and public-health significance
Research on synthetic cannabinoids has expanded considerably, but the evidence remains uneven. Some compounds have detailed receptor and metabolism studies, while others are known mainly from seized products or isolated clinical cases. The composition of commercial products also changes faster than clinical research can evaluate each new analogue.
K2 and Spice are best understood as product categories rather than as individual drugs. Their risks arise not only from the pharmacology of the compounds they contain, but also from unpredictable formulation, changing ingredients and the difficulty of identifying exposure in routine clinical settings.
Related synthetic cannabinoids
Compounds historically identified in K2/Spice products include JWH-018, JWH-073, AM-2201, UR-144, XLR-11, AB-FUBINACA and AB-CHMINACA. These examples belong to different structural families and do not form a pharmacologically uniform group.
